November 13, 2020 – Aziyo Biologics, Inc. (Silver Spring, MD) was awarded a group purchasing agreement with Premier Inc. (Charlotte, NC), for Premier’s Technology Breakthroughs Program.
Effective December 1, 2020, the new agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for Aziyo’s CanGaroo Envelope – a 510(k) FDA-cleared and CE-Marked extracellular matrix (ECM) envelope intended to securely hold a cardiac implantable electronic device (CIED) or an implantable neurostimulator to create a stable environment when implanted in the body.
The CanGaroo Envelope is a small intestine submucosa (SIS) ECM designed to mitigate complications deriving from implantable electronic devices and the shortcomings of synthetic envelopes. Once implanted, it creates a hospitable environment for the surrounding cells to migrate into the bio scaffold and start matrix turnover.
The natural, systemically vascularized pocket is remodeled into a surrounding layer of vital, vascularized tissue, potentially reducing the risk of capsular formation, migration and erosion of the implantable device through the skin, and complications associated with Twiddler’s syndrome.
The CanGaroo Envelope may also facilitate the process of implantation and of device removal during its replacement, as well as enhance patient comfort, the company says.